News

Alfredo Sadun, MD, PhD, details an unexpected outcome from a gene therapy in development for Leber hereditary optic neuropathy (LHON).

The goal is to provide an end-to-end operating system that unifies clinical, operational, and financial workflows.

Jeremiah Tao, MD, FACS, highlights essential safety strategies in oculofacial surgery, emphasizing cost-effective techniques to prevent complications and enhance patient care.

Recapping the Heidelberg Engineering International SPECTRALIS Symposium—and Beyond.

FDA issues a complete response letter to Outlook Therapeutics for ONS-5010, citing insufficient evidence of effectiveness for wet AMD treatment.

Surgical tools improve Schlemm canal access and enable earlier glaucoma care.

As myopia becomes a worldwide epidemic, the upcoming Paris workshop on September 8, 2025, will convene global leaders to discuss strategies, research priorities, and new treatment pathways.

Ahead of the September 8 meeting in Paris, the program co-chair of the event and current president of the American Academy of Ophthalmology discusses how the workshop aims to shape consensus on guidelines, research priorities, and emerging therapies in myopia control.

The study will be evaluating the safety, tolerability, and efficacy of QLS-111 in adult patients with normal tension glaucoma.

Innovation, adaptability, and clear communication are key to managing outcomes.

In episode 1, Bill Trattler, MD, shares practical advice on documentation, patient communication, keratoconus management, and advanced lens technology.

Surgeons navigate unpredictable healing and anatomy with customized strategies.

Kriya is developing gene therapies targeting chronic diseases such as geographic atrophy, trigeminal neuralgia, and type 1 diabetes.

Opioids like fentanyl effectively prevent sneezing during propofol sedation for periocular injections, enhancing patient safety in ophthalmic procedures.

Understand the anatomical risks, technique-specific benefits, and patient selection criteria

Alcon showcases new data at APACRS 2025, emphasizing advancements in IOL technology and surgical precision for improved patient outcomes.

Advanz Pharma and Alvotech announced AVT06, a biosimilar to Eylea, was approved for neovascular age-related macular degeneration

NCX 470 met the primary endpoint of non-inferiority in lowering intraocular pressure (IOP) from baseline compared to the standard of care, latanoprost 0.005%.

Included is the supplemental Biologics License Application (sBLA) for EYLEA HD seeking approval for both the treatment of macular edema following retinal vein occlusion (RVO) and the broadening of the dosing schedule to include every 4-week dosing across approved indications.